Literature DB >> 24696613

Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Ana Teresa P Carvalho1, Barbara C Esberard1, Renata S B Fróes1, Davy C M Rapozo1, Ana B Grinman1, Tatiana A Simão1, Juliana C V C Santos1, Antonio José V Carneiro1, Luis Felipe Ribeiro-Pinto1, Heitor S P de Souza1.   

Abstract

AIM: To analyze the prevalence of thiopurine-methyltransferase (TPMT) genotypes and their association with drug toxicity in inflammatory bowel disease (IBD) patients from southeastern Brazil.
METHODS: A total of 219 consecutive patients with IBD, of which 146 had Crohn's disease and 73 had ulcerative colitis, regularly seen at the outpatient unit of the Division of Gastroenterology at the University Hospital Pedro Ernesto of the State University of Rio de Janeiro, a tertiary referral center, were enrolled in this study from February 2009 to January 2011. We analyzed the presence of major TPMT genetic variants (TPMT 2, 3A, 3C) in IBD patients by means of a specific allele and RFLP-PCR. Genomic DNA was isolated from peripheral blood leukocytes by proteinase-K/Sodium Dodecyl Sulfate digestion and phenol-chloroform extraction. TPMT 2 (C238G), TPMT 3A (G460A/A719G), and TPMT 3C (A719G) genotypes were detected by real-time polymerase chain reaction followed by direct sequencing with specific primers. Clinical data were systematically recorded, and correlated with the genotype results.
RESULTS: The distribution of the selected TPMT gene polymorphism TPMT 2 (C238G), TPMT 3A (G460A/A719G), and TPMT 3C (A719G) genotypes was 3.6%, 5.4%, and 7.7% of the patients, respectively. Among the side effects recorded from patients taking azathioprine, 14 patients presented with pancreatitis and/or an elevation of pancreatic enzymes, while 6 patients had liver toxicity, and 2 patients exhibited myelosuppression/neutropenia. TPMT polymorphisms were detected in 37/219 patients (8 heterozygous for 2, 11 heterozygous for 3A, and 18 heterozygous for 3C). No homozygotic polymorphisms were found. Despite the prevalence of the TPMT 3C genotype, no differences among the genotype frequencies were significant. Although no association was detected regarding myelotoxicity or hepatotoxicity, a trend towards the elevation of pancreatic enzymes was observed for TPMT 2 and TPMT 3C genotypes.
CONCLUSION: The prevalence of TPMT genotypes was high among Brazilian patients. Variants genes 2 and 3C may be associated with azathioprine pancreatic toxicity in a IBD southeastern Brazilian population.

Entities:  

Keywords:  Azathioprine; Drug toxicity; Inflammatory bowel disease; Pancreatitis; Thiopurine-methyl-transferase

Mesh:

Substances:

Year:  2014        PMID: 24696613      PMCID: PMC3964403          DOI: 10.3748/wjg.v20.i12.3327

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Thiopurine methyltransferase phenotypes and genotypes in Brazilians.

Authors:  Marcelo Reis; Ana Santoro; Guilherme Suarez-Kurtz
Journal:  Pharmacogenetics       Date:  2003-06

3.  Progress in the diagnosis and treatment of inflammatory bowel disease.

Authors:  Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

4.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

5.  Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.

Authors:  Javier P Gisbert; Pilar Niño; Luis Rodrigo; Carlos Cara; Luis G Guijarro
Journal:  Am J Gastroenterol       Date:  2006-10-06       Impact factor: 10.864

6.  Thiopurine S-methyltransferase (TPMT) genetic polymorphisms in Mexican newborns.

Authors:  A González-Del Angel; C Bermúdez-López; M A Alcántara-Ortigoza; M Vela-Amieva; R A Castillo-Cruz; V Martínez; L Torres-Espíndola
Journal:  J Clin Pharm Ther       Date:  2009-12       Impact factor: 2.512

7.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

8.  Management of Crohn's disease in adults.

Authors:  Gary R Lichtenstein; Stephen B Hanauer; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2009-01-06       Impact factor: 10.864

9.  Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases.

Authors:  Jae Hee Cheon; Jae Hak Kim; Bo Young Kim; Seung Won Kim; Sung Yi Hong; Chang Soo Eun; Seong Soo Hong; Jeong-Sik Byeon; Tae Il Kim; Dong Soo Han; Suk-Kyun Yang; Kyoung Ryul Lee; Won Ho Kim
Journal:  Hepatogastroenterology       Date:  2009 Mar-Apr

Review 10.  Thiopurines in inflammatory bowel disease revisited.

Authors:  Florian Bär; Christian Sina; Klaus Fellermann
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

View more
  5 in total

Review 1.  Clinical Utility of Biomarkers in IBD.

Authors:  Gerhard Rogler; Luc Biedermann
Journal:  Curr Gastroenterol Rep       Date:  2015-07

2.  Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

Authors:  Mattheus C B Wielenga; Jooske F van Lidth de Jeude; Sanne L Rosekrans; Alon D Levin; Monique Schukking; Geert R A M D'Haens; Jarom Heijmans; Marnix Jansen; Vanesa Muncan; Gijs R van den Brink
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

3.  Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population.

Authors:  Polina Zalizko; Juris Stefanovics; Jelizaveta Sokolovska; Natalia Paramonova; Evija Klavina; Renars Erts; Vita Rovite; Janis Klovins; Aldis Pukitis
Journal:  Therap Adv Gastroenterol       Date:  2020-07-14       Impact factor: 4.409

4.  TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.

Authors:  Narinder Grover; Prateek Bhatia; Antriksh Kumar; Minu Singh; Deepesh Lad; Harshal S Mandavdhare; Jayanta Samanta; Kaushal K Prasad; Usha Dutta; Vishal Sharma
Journal:  BMC Gastroenterol       Date:  2021-08-23       Impact factor: 3.067

5.  Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis.

Authors:  Yue-Ping Liu; Hai-Yan Wu; Xiang Yang; Han-Qing Xu; Yong-Chuan Li; Da-Chuan Shi; Jun-Fu Huang; Qing Huang; Wei-Ling Fu
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.